Last edition
News about "Biohaven"
SK Biopharmaceuticals Secures Global Rights to Biohaven's Opakalim for Epilepsy
SK Biopharmaceuticals will gain exclusive global development and commercialisation rights to opakalim, strengthening its epilepsy portfolio alongside cenobamate and advancing its transition to a multi-product global pharma company.
Biohaven | 27/08/2026 | By News Bureau
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
Biohaven | 21/03/2026 | By News Bureau | 430
As part of the collaboration, Bexorg’s novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.
Biohaven | 12/06/2025 | By Darshana | 523
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy